An increasing number of venture capital investors are sounding the alarm on what the current public markets downturn could mean for private valuations. One recent warning came from Jeremy Levine of Bessemer Venture Partners:
Maryland Venture Fund and The Abell Foundation Top Investors in Round of Financing
Perceptive Navigation, LLC, a privately-held, Maryland-based medical device company developing solutions for the rapidly growing image- guided market, today announced the closing of its $500,000 seed round of financing, led by the Maryland Venture Fund (MVF) and The Abell Foundation. The proceeds will accelerate the development of Vu-Path, Perceptive Navigation’s ultrasound probe for minimally invasive interventional procedures, as well as enable its regulatory submission to the FDA.
Perceptive Navigation also announced the appointment of Todd Chappell as Chief Executive Officer. Chappell comes to Perceptive Navigation with fifteen years of experience working withearly-stage, venture-backed biotechnology companies. Most recently, he managed a portfolio of start-up pharmaceutical and medical device companies at BioHealth Innovation, Inc. (BHI), a regional innovation intermediary focused on commercializing market-relevant life science innovations, as an Entrepreneur-in-Residence. Perceptive was incubated at BHI under the leadership of Chappell prior to his appointment as Chief Executive Officer.
September 8th, Cattail Creek Country Club, Glenwood, MD
Biotech execs play for free in the tournament that will benefit The Little Things for Cancer & the Zaching Against Cancer Foundation organizations.
Welcome to the 2015 Biotech Invitational, a DogDenGolf managed event that is being supported by top executives at Medimmune, other Biotechnology companies and Vendors in the region. This year’s event will be held on September 8, 2015, at Cattail Creek Country Club in Glenwood, MD and will determine the Biotech Executive Golfers of the Year.
Proceeds from this event will benefit The Little Things for Cancer, a local non-profit providing support and services to cancer patients, and their caregivers. For detailed information on the programs and services that The Little Things provides, visit their website at www.tlt4c.org.
Cloud-based data company Inovalon Holdings will acquire D.C. health research and advisory firm Avalere Health in a deal worth $140 million, the companies announced Monday.
The move will enable Bowie-based Inovalon (Nasdaq: INOV) to expand into the pharmaceutical market and fuel growth in the use of big data analytics at life sciences companies, officials said. The deal is expected to close Sept. 1.
We are looking for the Most Rockin’ Business in the City!
Is it yours?
The 2nd Annual “Rockin’ in Rockville” Award is set to be handed out at this year’s REDI Resource Meetup (R2M) event in September.
This award, created to highlight the success, community engagement, and innovative practices of a Rockville-based company, is given out during Maryland Economic Development Week.
Durham venture capital fund Hatteras Venture Partners plans to announce Monday that it has raised more than $90 million for its fifth investment fund, giving it roughly 60 percent of its $150 million goal.
“We’re humbled and gratified that people would continue to have this level of confidence in us,” said Clay Thorp, co-founder and general partner.
Bayer HealthCare has launched its own digital health accelerator program in Berlin, Germany called “Grants4Apps,” selecting five digital health startups from around the globe that will advance their business ideas and technology in areas such as hormone tests, patient adherence, breathing patterns, clinical trials and vitamin deficiency. The selected five digital health startups will receive financial support of up to 50,000 Euro and will work out of the company’s pharmaceutical division in Berlin. Over the next four months, the startups will work with Bayer executives and seasoned entrepreneurs
The world’s first malaria vaccine got a green light on Friday from European drugs regulators who recommended it should be licensed for use in babies in Africa at risk of the mosquito-borne disease.
The shot, called RTS,S or Mosquirix and developed by British drugmaker GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative, would be the first licensed human vaccine against a parasitic disease and could help prevent millions of cases of malaria in countries that use it.
“The startup scene is starving for seed-stage investment right now.”
If you’ve ever spent time around a startup hub then you’ve probably heard some version of this comment before. Whether it’s currently the case in the D.C. area may be a fair question, and one that we’ve put to venture capitalists from some of the region’s most prominent firms—Revolution, New Atlantic Ventures and New Enterprise Associates.
Novartis has agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker’s stable of multiple sclerosis (MS) treatments.
Basel-based Novartis had previously acquired the rights to Ofatumumab for oncology indications, but it is currently being developed for relapsing remitting multiple sclerosis and other auto-immune conditions.